Penumbra (PEN) came out with quarterly earnings of $0.85 per share, beating the Zacks Consensus Estimate of $0.69 per share. This compares to earnings of $0.67 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 23.19%. A quarter ago, it was expected that this medical device maker would post earnings of $0.56 per share when it actually produced earnings of $0.64, delivering a surprise of 14.29%.Over the last four quarters, the com ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_____ to _____ Commission File Number: 001-37557 Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 05-0605598 (State or other ...

Exhibit 99.1 Penumbra, Inc. Reports Third Quarter 2024 Financial Results ALAMEDA, Calif., Oct. 30, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2024. 1 • Revenue of $301.0 million in the third quarter of 2024, an increase of 11.1% or 10.9% in constant currency , compared to the third quarter of 2023. • U.S. thrombectomy revenue of $162.1 million in the third quarter of 2024 increased 21.2 ...

ALAMEDA, Calif., Oct. 30, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2024. Revenue of $301.0 million in the third quarter of 2024, an increase of 11.1% or 10.9% in constant currency1, compared to the third quarter of 2023. U.S. thrombectomy revenue of $162.1 million in the third quarter of 2024 increased 21.2% and 5.4% compared to the third quarter of 2023 and second quarter of 2024, re ...

The latest news from the lab, plus an analyst's bullish move, combined to put some zip in the company's shares. News about one of Penumbra's (PEN 4.02%) development programs and an analyst's price target raise combined to boost the medical device company's stock on Monday. Its price rose by over 4%, giving the stock a clear victory over the S&P 500 index, which increased by 0.8%. Good news from the lab Penumbra announced that it has completed patient enrollment for a clinical trial to evaluate its Penumbra ...

ALAMEDA, Calif., Oct. 14, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the completion of enrollment in its THUNDER clinical study for patients with acute ischemic stroke. THUNDER is evaluating the safety and efficacy of the company's latest computer assisted vacuum thrombectomy (CAVT™) technology, Penumbra System™ with Thunderbolt™ Aspiration Tubing, for the removal of blood clots in the brain. Penumbra announced the completion of enrollment in its THU ...

Penumbra, Inc. (PEN) is likely to grow in the coming quarters, backed by the strength exhibited in the Thrombectomy business. The company's robust portfolio expansion looks promising. However, the impact of forex woes is a headwind. Competitive disadvantages also add to the worry. In the past year, this Zacks Rank #3 (Hold) company has lost 16.2% against the industry's 17.8% growth and the S&P 500's 30.4% rise. The global healthcare provider company has a market capitalization of $8.67 billion. PEN beat on ...

ALAMEDA, Calif., Oct. 2, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the third quarter 2024 after market close on Wednesday, October 30, 2024 at 4:30 PM Eastern Time. A press release with third quarter 2024 financial results will be issued after market close that day. Webcast & Conference Call Information The conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 5872954), or the w ...

The company might just be the right kind of business operating at the right time in history. Veteran medical device maker Penumbra (PEN 4.55%) got a shot of good news on Wednesday. An analyst initiated coverage of the company's stock with a rather bullish review, and investors took this to heart. Collectively, they pushed Penumbra's share price up by almost 5% on a day when the S&P 500 index performed sluggishly with a 0.3% decline. Initiated with a buy recommendation Just after market close on Tuesday, Sti ...

Alameda, CA-based Penumbra, Inc. (PEN) has secured the CE Mark in Europe for its newest computerassisted vacuum thrombectomy (CAVT) technologies, Lightning Flash 2.0 and Lightning Bolt 7. Lightning Flash 2.0 is the most advanced mechanical thrombectomy system available to address venous and pulmonary thrombus while the Lightning Bolt 7 stands out as the most powerful arterial thrombectomy system in the market. The latest innovations further enhance the company's neuro and vascular portfolios. Likely Trend o ...